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Abstract. PSEN1 mutations are the most frequent cause of autosomal dominant Alzheimer’s disease (ADAD), and show
nearly full penetrance. There is presently increasing interest in the study of biomarkers that track disease progression in
order to test therapeutic interventions in ADAD. We used white mater (WM) volumetric characteristics and diffusion tensor
imaging (DTI) metrics to investigate correlations with the normalized time to expected symptoms onset (relative age ratio)
and group differences in a cohort of 36 subjects from PSEN1 ADAD families: 22 mutation carriers, 10 symptomatic (SMC)
and 12 asymptomatic (AMC), and 14 non-carriers (NC). Subjects underwent a 3T MRI. WM morphometric data and DTI
metrics were analyzed. We found that PSEN1 MC showed significant negative correlation between fractional anisotropy (FA)
and the relative age ratio in the genus and body of corpus callosum and corona radiate (p < 0.05 Family-wise error correction
(FWE) at cluster level) and positive correlation with mean diffusivity (MD), axial diffusivity (AxD), and radial diffusivity
(RD) in the splenium of corpus callosum. SMC presented WM volume loss, reduced FA and increased MD, AxD, and RD
in the anterior and posterior corona radiate, corpus callosum (p < 0.05 FWE) compared with NC. No significant differences
were observed between AMC and NC in WM volume or DTI measures. These findings suggest that the integrity of the WM
deteriorates linearly in PSEN1 ADAD from the early phases of the disease; thus DTI metrics might be useful to monitor the
disease progression. However, the lack of significant alterations at the preclinical stages suggests that these indexes might
not be good candidates for early markers of the disease.
Keywords: Alzheimer’s disease, diffusion tensor imaging, magnetic resonance imaging, presenilin 1, white matter
∗Correspondence to: Raquel Sa´nchez-Valle, Alzheimer’s Dis-
ease and Other Cognitive Disorders Unit, Department of Neu-
rology, Hospital Clı´nic, Villarroel, 170, 08036 Barcelona, Spain.
Tel.: +34 932275785; Fax: +34 932275783; E-mail: rsanchez@
clinic.ub.es.
INTRODUCTION
AsmallminorityofAlzheimer’sdisease(AD)cases
are inherited with an autosomal dominant pattern of
inheritance, caused by a mutation in the presenilin-1
(PSEN1), amyloid precursor protein, or presenilin-2
genes. These forms, also called autosomal dominant
AD (ADAD), show almost 100% penetrance and
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present an early age of onset, which is relatively pre-
dictable in a given family [1] and thus, represent a
population in whom treatment could be initiated at
early phases of the disease, even at a presymptomatic
stage [2]. In this sense, two trials: the Dominantly
Inherited Alzheimer Network Trials Unit (DIAN-
TU) (ClinicalTrials.gov Identifier: NCT01760005)
[2, 3] and the Alzheimer’s Prevention Initiative (API)
Colombian trial (NCT01998841) [2, 4] are already
ongoing and aim to evaluate the safety and efficacy
of different drugs in ADAD. Although regulatory
agencies require the presence of significant benefit
in cognition even in prevention treatment trials, there
is considerable effort in searching for non-invasive
biomarkers that could act as surrogate markers or pro-
vide evidence of disease modification [5, 6].
AD is traditionally considered mainly a disease of
the grey matter (GM). In this sense, to date, mor-
phometric GM or whole brain measures are the main
neuroimaging biomarkers included in clinical trials,
based on the extensive literature in mild cognitive
impairment and dementia due to AD patients, both
in sporadic [7] and ADAD [8–10]. However, there
is some evidence that suggest that GM morphome-
tric measures may suffer unexpected effects with
anti-amyloid therapies [11] or present non-linear tra-
jectories in different brain areas [12–15] that may
lead to difficulty in their interpretation in clinical
trials. On the other hand, thanks to the advances
in MRI-related techniques, white-matter (WM) tract
disruption is becoming a well described early event in
AD, and although it is thought to be mainly secondary
to GM damage, other hypotheses, that WM and GM
loss are different effects of a common upstream
pathological process, have been also proposed
[16, 17].
Diffusion tensor imaging (DTI) measures the diffu-
sion directionality of water molecules in brain tissue,
and the study of the different DTI metrics could be
of interest for capturing additional or complemen-
tary markers of neurodegeneration [18]. In this sense,
fractional anisotropy (FA) reflects how directionally
constrained the diffusion of water is along axons and
lower FA supports loss of WM integrity. Axial diffu-
sivity (AxD) measures diffusion parallel to axonal
fibers, radial diffusivity (RD) perpendicular diffu-
sion, and mean diffusivity (MD) the average rate of
diffusion in all directions, and generally increases
with WM injury [19].
Prior DTI studies in sporadic AD have reported
lower FA and increased MD, RD, and/or AxD,
throughout WM, mainly in the corpus callosum,
fornix, cingulum, superior longitudinal fasciculus,
and inferior longitudinal fasciculus [19–22]. Some
of these studies also demonstrated strong correlation
with widely-used clinical measures [20, 23, 24].
There are scarce and conflicting data about WM
abnormalities and WM DTI metrics in ADAD, but
based on the available results in both sporadic and
ADAD, we hypothesized that WM in ADAD would
deteriorate with disease progression. Thus, here, we
investigate WM structural and DTI metrics in ADAD
due to PSEN1 mutations and their correlation with
the time to expected symptoms onset in order to pro-
vide exploratory evidence of the potential use of these
markers in ADAD trials.
MATERIALS AND METHODS
Subjects
Thirty-six adult participants from ADAD families
with 9 different PSEN1 mutations (M139T, S169P,
G209E, R220G, L235R, K239N, L282R, L286P,
I439S) were recruited from the genetic counseling
program for familial dementias (PICOGEN) at the
Hospital Clinic, Barcelona, Spain [12]. Subjects were
made aware of their at-risk status for genetic AD in
a session of genetic counseling and were given the
option of knowing their genetic status through the
genetic counseling protocol. The study was approved
by the Hospital Clinic ethics committee, and all sub-
jects gave written informed consent.
Genetic analysis
Genomic DNA was extracted from peripheral
blood using the QIAamp DNA Blood Mini Kit
(Qiagen). Mutation screening was performed by
direct sequencing.
Clinical and neuropsychological
characterization
Subjects underwent clinical and cognitive assess-
ments, and a comprehensive neuropsychological
battery was also administered, as described previ-
ously [13].
Subjects were classified as asymptomatic if they
had no memory complaints, they scored 0 on the
Clinical Dementia Rating (CDR) scale, and their
cognitive performance was within the mean ± 1.5
SD with respect to control scores from their age
and educational level on all the cognitive tests.
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Participants were classified as symptomatic if their
CDR score was >0 or if their cognitive performance
was more than 1.5 SD below the mean with respect
to their age and educational level on any cognitive
test.
To evaluate the time to expected symptoms onset
of each mutation carrier (MC), we calculated the
relative or adjusted age as the subject’s age relative
to the median age of onset in their family (absolute
age – median age of onset in their family), similar to
previous studies in ADAD [1, 8–10, 12]. The range
of the median age of onset in the families included in
this study is wide (range 31–61 years). As the same
distance to symptoms onset expressed in years might
have different biological effects in subjects with dif-
ferent expected ages of onset (that is, a period of
10 years is almost one third of the biological life
until symptoms onset in subjects with an expected
age of onset of 31 but only one sixth in subjects with
expected symptoms onset at 61), we defined and cal-
culated for each mutation carrier the relative age ratio
defined as the relative age divided by the median age
of onset in the family (relative age ratio = [absolute
age – median age of onset in their family]/median age
of onset in their family) in order to compare subjects
from different families with different median ages of
onset.
MRI scanning
All subjects were scanned in the same 3T scan
(Siemens Trio Tim, Siemens, Germany). The
study included a high-resolution 3D structural
dataset (T1-weighted MP-RAGE, voxel size = 1.0 ×
1.0 × 1.0 mm, TR = 2300 ms, TE = 2.98 ms, 240
slices, FOV = 256 mm, matrix size = 256 × 256, slice
thickness = 1 mm). The DTI protocol consisted of an
echo-planar imaging (EPI) sequence with coverage
of the whole head (30 directions + b0 image, with two
repeated acquisitions, TR = 7600 ms, TE = 89 ms, 60
slices, slice thickness = 2 mm, distance factor = 0%,
FOV = 250 mm, matrix size = 122 × 122, voxel
size = 2 × 2 × 2 mm). Two identical DTI runs were
acquired.
Preprocessing of volumetric data
The T1-weigthed images were visually inspected
for possible artifacts and Fluid-attenuated inver-
sion recovery (FLAIR) T2-weighted images for
white matter hyperintensities. Next, a VBM-type
pre-processing was conducted. Default segmentation
implemented in SPM12 (Wellcome Trust Centre for
Neuroimaging, UK) was used for extracting WM tis-
sue class. Normalization to the same stereotaxic space
was performed by Dartel [25]. Finally, warped WM
images were modulated and smoothed with 8 mm of
FWHM.
Preprocessing of DTI data
Data were visually inspected for possible artifacts
and damaged volumes. Next, the two runs acquired
were concatenated in a single file and reoriented
jointly to the structural MRI data. FA, MD, AxD,
and RD maps were obtained using FDT (FMRIB’s
Diffusion Toolbox) implemented in FSL (FMRIB
Software Library, Oxford, UK). Prior to the DTI cal-
culation, diffusion images were corrected for eddy
current distortion, corrected for motion, and regis-
tered to b0 image using FLIRT [26].
For intra-subject registration, SPM12 was used.
Diffusion metrics (FA, MD, RD, and AxD) were
first linearly co-registered to their corresponding
T1 images. Next, inter-subject registration was per-
formed using Dartel [25]. It was done using same
flow fields from the VBM-type preprocessing above
described, these flow fields were applied to the diffu-
sion data that were finally normalized to the MNI
space. At the end, the non-linearly registered dif-
fusion data were smoothed applying an isotropic
Gaussian kernel with 8 mm of FWHM.
Statistical analysis
The same statistical procedures were applied to
structural and diffusion data using SPM12 package.
Firstly, we performed linear regression with the rela-
tive age ratio in PSEN1 MC. To avoid redundancies
with the relative age ratio in the matrix design, only
gender was used as covariate. For the VBM analy-
sis, total intracranial volume (TIV) was additionally
entered as global.
Secondly, we performed a t-test comparison
between groups: NC versus AMC, NC versus SMC,
and AMC versus SMC. The design included age and
gender as covariates. TIV was used as a covariate only
in the VBM analysis.
Statistical analyses were performed using a WM
mask in the MNI space, obtained from the own cus-
tomized warped WM. The mask was fitted using
absolute threshold 0.25. The fornix region extracted
from the JHU-DTI with matter atlas (John Hop-
kins University, Laboratory of brain anatomical MRI;
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Table 1
Demographic data and Mini-Mental State Examination (MMSE)
score. Values are mean (SD); ∗p < 0.01 compared with NC
and AMC
NC (n = 14) AMC (n = 12) SMC (n = 10)
Absolute age 39.04 (9.5) 39.18 (10.37) 46.63 (9.13)∗
in years (SD)
Relative age –8.89 (8.70) –12.90 (8.72) 2.83 (3.27)∗
in years (SD)
Relative age –0.18 (0.16) –0.25 (0.17) 0.061 (0.07)∗
ratio (SD)
Gender, M/W 6/8 3/9 4/6
Formal education 12.07 (2.20) 13.25 (2.49) 9.6 (4.14)
in years (SD)
MMSE 29.43 29.25 21.00∗
(SD, range) (0.64, 28–30) (1.05, 27–30) (5.27, 12–28)
29.43 29.25 21.00
cmrm.med.jhmi.edu) was added to this mask to
ensure this area was also included in the statistics.
Statistical analyses were performed by fitting a
voxel-wise general linear model (GLM), resulting
maps were corrected for multiple comparisons using
Family-wise Error (FEW) correction. We used a sig-
nificance threshold of corrected FWE p < 0.05 from a
map uncorrected p < 0.001 (the map became then cor-
rected at cluster level). Only clusters wider than 50
voxels were considered. Brain locations of the results
were reported by means of the JHU-DTI white-matter
atlas.
For demographics and clinical data, group analyses
were conducted using PASW (Predictive Analytics
SoftWare, IBM Corp.) v.18. Comparisons between
groups were performed using the two-tailed Student’s
t test or ANOVA for continuous variables, and a chi
square test for categorical variables.
RESULTS
Demographics and clinical classiﬁcation
Demographic and clinical data of the participants
are summarized in Table 1.
Twenty-two subjects were mutation carriers with a
mean absolute age of 42.57 years (SD 10.32). Twelve
of the mutation carriers were AMC and 10 SMC
(Table 1), 7 of the SMC met criteria for dementia at
inclusion. Fourteen subjects were NC, with a mean
absolute age of 39.18 years (SD 10.37). All the NC
were cognitively normal and scored 0 on CDR. Abso-
lute age did not differ between NC and the whole
sample of mutation carriers or AMC, but as expected,
SMC were older than both NC and AMC, and pre-
sented significantly lower MMSE scores (p < 0.01).
No relevant WM hyperintensities (Fazekas scale <1)
have been observed in participants at visual inspec-
tion in FLAIR weighted images.
White matter metrics and the relative age ratio
in PSEN1 mutation carriers
FA values inversely correlated with the relative age
ratio in PSEN1 mutation carriers (Fig. 1). Significant
correlations were found in right anterior corona radi-
ata (Z max = 4.31, k = 1905 voxels, MNI coordinate
[18, 32, 16]) involving the genu and body of cor-
pus callosum (Fig. 1a). The forceps minor, cingulate
gyrus, inferior fronto-occipital, and uncinate fasci-
culus were also affected. Another significant cluster
was found in the left anterior corona radiate and ante-
rior thalamic radiation (Z max = 4.28, k = 678 voxels,
MNI coordinate [–15, 27, 22]), also including the
genu and body of corpus callosum.
MD values directly correlated with the relative
age ratio in PSEN1 mutation carriers (Fig. 1b).
Clusters distribution appeared bilateral and symmet-
ric. The first cluster (Z max = 4.03, k = 2687 voxels,
MNI coordinate [16, –38, 8]) was localized in the
right splenium and body of corpus callosum, and
the fronto-occipital fasciculus. This cluster extended
toward the right posterior thalamic radiation and
retrolenticular part of the internal capsule and the
fornix (cres)/stria terminalis. The second cluster
(Zmax = 3.91, k = 1656 voxels, MNI coordinate [–15,
–46, 0]) was centered in the left cingulum (hippocam-
pus) and forceps major tract and the fornix (cres)
stria terminalis; it also reached the posterior thalamic
radiation and the retrolenticular part of the internal
capsule.
AxD and RD values showed similar results to MD
values and presented positive correlation with the rel-
ative age ratio in areas of the splenium and body
of corpus callosum, posterior thalamic radiation and
retrolenticular part of the internal capsule and the
fornix (cres)/stria terminalis.
We did not find any significant correlation between
DTI measures and subjects’ age in NC.
The volumetric analysis showed an inverse corre-
lation between WM volume and the relative age ratio
in PSEN1 mutation carriers in the fornix (column and
body) (p < 0.001 unc., Zmax = 4.11, k = 68 voxels,
MNI coordinate [–2, –21, 18]), and the body of cor-
pus callosum (p < 0.001 unc., Z max = 3.78, k = 107
voxels, MNI coordinate [–2, –24, 20]). However,
these clusters did not survive the threshold at a cluster
level.
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Fig. 1. DTI metrics correlation with the relative age ratio in PSEN1 mutation carriers (p < 0.05 FWE corrected at cluster-level): (a) Areas
of significant inverse correlation with Fractional anysotropy (FA) values and fitted line plot of FA values in right corona radiata (Z max:18,
32, 16); Adjusted R-squared = 0.61∗. (b) Areas of positive significant correlation with mean diffusivity (MD) values and fitted line plot of
MD values in splenium of corpus callosum (Z max: 16 –38, 8). Adjusted R-squared = 0.56∗ (∗models were adjusted by absolute age).
White matter volumetric data: group analysis
PSEN1 SMC showed reduced WM volume com-
pared with NC in the anterior and posterior corona
radiata and posterior thalamic track the left supe-
rior and inferior longitudinal fasciculus, inferior
fronto-occipital, and uncinated fasciculus (Z = 4.07,
k = 3737, [–44, –38, 0]) (p < 0.05 FWE at cluster
level (Fig. 2)). A second significant cluster was
observed in the genus of corpus callosum, cingulate
gyrus, and the forceps minor (Z = 8.34, k = 1476,
[–8, 30, 15]); it included the inferior fronto-temporal
fasciculus, anterior thalamic radiation, superior
longitudinal fasciculus, and forceps minor tracts.
No significant differences were observed between
AMC and NC.
Diffusion tensor imaging metrics: group analysis
SMC showed significant reduced FA compared
with NC in the body of corpus callosum and bilat-
eral anterior corona radiata (Z = 5.22, k = 2235), [28,
34, 12]) and posterior thalamic radiation (Fig. 3).
SMC presented increased MD, RD and AxD in
extensive areas of WM (Z = 5.65, k = 75726), [20,
–32, 3]): genum, body and splenium of corpus
callosum, cingulate gyrus, superior and inferior
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Fig. 2. Areas of WM volume loss in SMC compared with NC
(p < 0.05 FWE at cluster level; age and gender as covariates).
Fig. 3. DTI metrics in symptomatic mutation carriers (SMC)
compared with non-carriers (NC). (a) Fractional anisotropy:
SMC < NC. (b) Mean diffusivity: SMC > NC (p < 0.05 FWE
corrected at cluster level; age and gender as covariates).
longitudinal fasciculi, fronto-occipital fasciculi, ante-
rior and posterior corona radiata, and posterior
thalamic radiation.
No significant differences were observed in AMC
compared with NC.
DISCUSSION
We performed a morphometric analysis of WM
PSEN1 ADAD to assess the integrity of WM in these
subjects and to study the relationship between WM
integrity and time to expected symptoms onset. With
DTI, we found that FA, MD, AxD, and RD values
correlated with distance to symptoms onset in the
whole sample of MC. However, group differences,
both in DTI metrics and volumetric analyses, were
only significant in the SMC group.
To the best of our knowledge, this is the first study
to examine the relationship of DTI metrics and the
relative distance of symptoms onset in ADAD. FA
values decrease linearly in the genus and anterior
body of the corpus callosum and anterior corona radi-
ate from values of subjects far from symptoms onset
to those of subjects older than expected age of onset
and already symptomatic. The maps of areas with
significant correlation of FA with the relative distance
of symptoms onset and those of areas with significant
FA reduction in SMC are quite similar, suggesting
that the disconnection process is a progressive part of
the pathophysiological mechanism underlying brain
alterations in ADAD. As expected, MD, AxD, and
RD values evolve in the opposite sense, with increas-
ing values as the subjects became closer to symptoms
onset or already symptomatic, in the body and sple-
nium of corpus callosum.
As regards as WM volumetric analysis, there are
also scarce studies available focused in the study of
the WM integrity in ADAD. Cash et al. performed a
VBM study in the Dominantly Inherited Alzheimer
Network (DIAN) cohort and found that WM was
reduced in cingulum, fornix, and areas close to the
posterior cingulate and precuneus in 50 SMC com-
pared with NC. The authors stated that caution should
be taken when interpreting these data, due to techni-
cal difficulties in the WM parcellation using VBM.
As most of the WM changes overlap areas that pre-
dominantly contain GM, the results may reflect GM
atrophy rather than actual WM difference [27]. In
our morphometric study, SMC also showed volume
loss in relevant WM areas. We did not find signifi-
cant differences between AMC and NC. However, as
Cash et al. suggested, we also think that VBM analy-
sis might not be the optimal technique to study WM
alterations in ADAD.
With respect to previous studies on DTI metrics
in ADAD, Ringman et al. [28] found that ADAD
mutation carriers (n = 12), presented decreased mean
whole brain white-matter FA and FA values in the
columns of the fornix, areas of the perforant pathways
bilaterally and left orbitofrontal lobe relative to that of
NC (n = 8) in a region of interest (ROI) analysis. They
also found that FA in the columns of the fornix and
left orbitofrontal lobe were significantly decreased in
the eight presymptomatic mutation carriers. In our
study, neither the fornix nor the orbitofrontal lobe
arose as significant areas of different FA values in any
of the group comparisons performed, although we
performed a whole-brain analysis instead ROI type of
analysis. In this sense, our results were more similar
to those of Parra et al. [29] performed in the Colom-
bian E180A PSEN1 cohort, even if they also used the
ROI approach, and AMC versus NC analysis revealed
no significant differences in any of the DTI metrics.
In contrast, and similar to our findings, group com-
parisons between SMC and NC showed that patients
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had higher MD in the body and splenium of corpus
callosum, cingulum, and frontal WM.
Another study performed in a cohort of 10 PSEN1
and APP symptomatic and asymptomatic MC also
showed significantly increased MD in the inferior and
superior longitudinal fasciculus and cingulum in MC
compared with controls [30]. However, in the same
study, MD was still significantly increased in these
areas when the presymptomatic MC were analyzed
alone. Subtle differences in the methods of analy-
sis, relative age of the AMC, or type of mutations
included could account for these differences with our
results. In this sense, a recent series [31] and several
previous case reports [32–34] have underlined rel-
evant differences in the WM abnormalities, both in
neuroimaging and neuropathological studies, within
ADAD cases, related to the site of the causal mutation
in the PSEN1 or APP genes.
We think that the main limitation of our study is
the relatively small sample size that may limit the
interpretation of the results, especially in the AMC
group analysis, and prevent some potential analysis
of interest. However, previous investigations of WM
measures in ADAD neuroimaging have similar sam-
ple sizes and our main results survived a correction
for multiple comparisons.
In summary, we think that our findings support
the idea that the WM deteriorates progressively in
PSEN1 ADAD with disease evolution. In this sense,
DTI metrics, even if they may not be useful to detect
early preclinical phases of the ADAD neuropatholog-
ical process, might monitor the disease progression.
Longitudinal and multicentric studies will be needed
to confirm these exploratory results.
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